<DOC>
	<DOCNO>NCT02222324</DOCNO>
	<brief_summary>This thorough QT ( TQT ) study take place healthy subject administer single dos study drug . It randomize , double-blind , placebo active-controlled , 4-treatment crossover study . Subjects randomize equal ratio one 12 possible treatment sequence . Each treatment sequence comprise 4 treatment .</brief_summary>
	<brief_title>A Study Evaluate Effects E2609 QTc Interval Healthy Subjects</brief_title>
	<detailed_description>The study consist 2 phase : Prerandomization Randomization . The Prerandomization Phase 2 period : Screening ( 27 day ) Baseline Period 1 ( 1 day ) . Eligibility determine Screening Period . The Randomization Phase consist 8 period : Treatment Period 1 , Baseline Period 2 , Treatment Period 2 , Baseline Period 3 , Treatment Period 3 , Baseline Period 4 , Treatment Period 4 , Follow-Up Period . Each Baseline Period last 1 day , follow corresponding treatment period . On first day treatment period , subject receive single dose assign study drug . During treatment period , subject require stay clinical unit baseline period 24 hour postdose . Subjects release clinic undergo washout interval least 13 day , time return additional PK sampling .</detailed_description>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Inclusion Criteria Subjects must meet follow criterion include study : 1 . Healthy , nonsmoking , male female subject age great equal 18 year less equal 55 year old time inform consent 2 . Body mass index ( BMI ) great equal 18 less equal 30 kg/m2 Screening 3 . Females must lactate pregnant Screening Baseline ( document negative betahuman chorionic gonadotropin [ BhCG ] ) . A separate baseline assessment require negative screening pregnancy test obtain 72 hour first dose study drug . 4 . Females childbearing potential must unprotected sexual intercourse within 30 day study entry must agree use highly effective method contraception ( eg , total abstinence , intrauterine device , doublebarrier method [ condom plus diaphragm spermicide ] , vasectomize partner confirm azoospermia , oral contraceptive contraceptive implant ) throughout entire study period 30 day study drug discontinuation . If currently abstinent , subject must agree use double barrier method describe becomes sexually active study period 30 day study drug discontinuation . Hormonal contraceptive ( oral implant ) permit form contraception study . All female consider childbearing potential unless postmenopausal ( amenorrheic least 12 consecutive month , appropriate age group without know suspected cause ) sterilize surgically ( ie , bilateral tubal ligation , total hysterectomy bilateral oophorectomy , surgery least one month dose ) . 5 . Male subject must successful vasectomy ( confirm azoospermia ) female partner must meet criterion ( ie , childbearing potential practicing highly effective contraception throughout study period 30 day study drug discontinuation ) . No sperm donation allow study period 90 day study drug discontinuation . Exclusion Criteria Subjects meet follow criterion exclude study : 1 . Clinically significant illness require medical treatment within 8 week clinically significant infection require medical treatment within 4 week dose 2 . Evidence disease may influence outcome study within 4 week dose ( eg , psychiatric disorder disorder gastrointestinal tract , liver , kidney , respiratory system , endocrine system , hematological system , neurological system , cardiovascular system , subject congenital abnormality metabolism ) 3 . Any history gastrointestinal surgery may affect PK profile study drug ( eg , hepatectomy , nephrectomy , digestive organ resection ) 4 . Any clinically abnormal symptom organ impairment find medical history , physical examination , vital sign , ECG finding , laboratory test result require medical treatment Screening Baseline Periods 5 . History medical condition , opinion investigator , may interfere study procedure compromise subject safety 6 . A prolonged QT/corrected QT interval ( QTc ) interval ( QTc great 450 msec ) demonstrate mean triplicate ECGs Screening Baseline Periods 7 . History risk factor torsade de pointes use concomitant medication prolong QT/QTc interval 8 . Persistent systolic blood pressure ( BP ) great 130 mmHg less 90 mmHg diastolic BP great 85 mmHg less 60 mmHg Screening Baseline Periods 9 . Heart rate le 50 great 100 beats/minute Screening Baseline Periods 10 . History prolong QT/QTc interval 11 . Left bundle branch block Screening Baseline Periods 12 . History myocardial infarction active ischemic heart disease 13 . History clinically significant arrhythmia uncontrolled arrhythmia 14 . Any clinically significant ECG abnormality Screening Baseline Periods 15 . Known history clinically significant drug allergy ( include study drug excipients ) Screening Baseline 16 . Known history food allergy presently experience significant seasonal perennial allergy Screening Baseline Periods 17 . Active viral hepatitis ( B C ) demonstrate positive serology Screening 18 . History drug alcohol dependency abuse within 2 year Screening , positive urine drug alcohol test Screening Baseline Periods 19 . Use recreational drug 20 . Intake caffeinated beverage food within 72 hour dose 21 . Intake nutritional supplement , juice , herbal preparation food beverage may affect various drug metabolize enzyme transporter ( eg , alcohol , grapefruit , grapefruit juice , grapefruitcontaining beverage , apple orange juice , vegetables mustard green family [ eg , kale , broccoli , watercress , collard green , kohlrabi , brussel sprout , mustard ] , charbroiled meat ) within 1 week dose 22 . Intake herbal preparation contain St. John 's Wort within 4 week dose 23 . Use prescription drug within 4 week dose 24 . Intake overthecounter ( OTC ) medication within 2 week dose 25 . Smoking use tobacco nicotinecontaining product within 4 week dose 26 . Engagement strenuous exercise within 2 week dose ( eg , marathon runner , weight lifter ) 27 . Currently enrol another clinical trial use investigational drug device within 30 day precede informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>QTc Interval</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>